4/24 TEP for Meds Reconciliation

CMS is seeking nominations for members of  Technical Expert Panel to develop one or more quality measures related to medication reconciliation and management for ESRD patients.  Nominations are due by April 24, 2017.  For details see https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/TechnicalExpertPanels.html#ESRD%20Reconciliation .

SC 2/19 UKEEP Medications

The UCLA Kidney Education Enhancement Program (UKEEP) will present a free seminar for patients on February 19, 2017 in Santa Monica about Medications: What You Need to Know.  RSVP requested.  For details see https://s3-us-west-2.amazonaws.com/nwrn.org/files/N/UKeep021917.pdf .  Don’t forget to mark your calendar for the March 26, 2017 UKEEP Kidney Fair.

9/22-23 AAKP Patient Meeting

There’s still time to register for the AAKP National Patient Meeting in Nashville September 23-25, 2016 on the theme Explore Your Future Today.  Topics include transplantation and living donation, patient engagement, diet and nutrition, treatment options and medications, and patient safety.  AAKP and the Living Kidney Donor Network, a national non-profit organization, will host a hands-on workshop Having Your Donor Find You! on Sept. 22, 2016.  For complete details, see https://www.aakp.org/community/programs-events/aakp-national-patient-meeting.html .

Warning: Kidney Damage from Canagliflozin, Dapagliflozin

The FDA has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR).  The labels now include information about acute kidney injury and  recommendations to minimize this risk.  For full details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm506554.htm .

October Patient Poster: Open Enrollment

We’ve posted the October Monthly Patient Flyer/Poster on the Network website.  This one has details about “Medicare Open Enrollment is October 16 – December 7,” including phone numbers for State Health Insurance Assistance Programs and for Social Security, which may be able to provide extra help paying for medications, in addition to your Medicare Prescription Drug Plan.  If you have questions or suggestions for future Patient Flyers, please contact Patient Services Director Lisa Hall at lhall@nw16.esrd.net .  Find this and all of our Monthly Patient Posters at:

FDA Warning re K-Binder Drug Interactions

The FDA has approved a new Potassium Binder, Veltassa (patiromer for oral suspension) to treat non-life-threatening hyperkalemia.  For details see:

The FDA has warned that Veltassa will also bind many other orally administered drugs, and consequently Veltassa comes with a boxed warning that it should not be taken within six hours of other orally administered drugs.  

The FDA has also warned that Kayexalate (sodium polystyrene sulfonate, generics Kionex, SPS) may have the same issue, has called for studies of its drug interactions, and advises that for now, out of caution, it too should not be taken within six hours of other orally administered drugs.  For details see: